CARDIOVASCULAR: Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?

Audio Journal of Cardiovascular Medicine Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention? REFERENCE: ACC New Orleans, March 24th Late Breaking Trials DAVID MOLITERNO, University of Kentucky, Lexington An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC's New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.